AzTrials
AzTrials

Liver AblationDUALNCT07900984

A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation

An observational study of Liver Ablation and Liver Cancer, run by Varian, a Siemens Healthineers Company.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Intelliblate Microwave Ablation (MWA) System
Type of treatment
Medical device
How many people
63 participants
Where
No sites listed yet
Study dates
Oct 2026to Mar 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Subjects will have undergone at least one dual channel MWA treatment in the liver using the Intellblate MWA system and have at least 30 days of follow-up for safety and 8 weeks (-4 weeks, +8 weeks) follow-up for complete ablation evaluation

Who may be able to join

  • Undergone at least one MWA treatment in the liver using dual channel ablation on the Intelliblate MWA system.
  • At least 30 days of follow-up post treatment for safety and 8 weeks (-4 weeks, +8 weeks) follow-up for imaging to assess complete ablation.

Who cannot join

  • Undergone radioembolization or other radiotherapy to the liver.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Clinical Trial Manager contact

5102799833

febasusan.sam@siemens-healthineers.com

Clinical Trial Manager contact

+46 761471751

Ashley.Keefe@siemens-healthineers.com

About this study

This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.

Read the detailed description

This study is a retrospective multi-center registry designed to evaluate the safety and performance of the Intelliblate Microwave Ablation (MWA) System with dual channel simultaneous microwave ablation of the liver.

Being tested
Intelliblate Microwave Ablation (MWA) System
Keywords
retrospective registry, liver ablation, intelliblate, dual channel microwave ablation
Medical subject headings
Liver Neoplasms, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intelliblate Microwave Ablation (MWA) SystemDevice

    Subjects will have undergone at least one dual channel MWA treatment in the liver using the Intellblate MWA system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 30-Day Major Complication Rate

    30-day post-treatment Major Complication Rate (Grade 3 or above) according to CTCAE criteria. This evaluates the safety of the IntelliBlate MWA System using dual-channel simultaneous microwave ablation of the liver.

    Measured: Treatment to 30 days of follow-up

Secondary outcomes (1)

  1. Complete Ablation Rate

    Complete Ablation Rate based on post-procedure imaging. This evaluates the performance/effectiveness of the IntelliBlate MWA System.

    Measured: 8 weeks post-treatment, with an allowable window of -4 weeks to +8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionFeb 2027 (estimated)
  4. Study completionMar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
63 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07900984
Sponsor's protocol ID
VAR-2026-01
Acronym
DUAL
Status last verified
Oct 2026
First submitted
21 Oct 2026
Last updated
28 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided: Individual participant data could be shared with each site for their own patients upon request.

Publications

  • Laeseke P, Ng C, Ferko N, Naghi A, Wright GWJ, Zhang Y, Laidlaw A, Kalsekar I, Laxmanan B, Ghosh SK, Zhou M, Szapary P, Pritchett M. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis. Lung Cancer. 2023 Aug;182:107259. doi: 10.1016/j.lungcan.2023.107259. Epub 2023 Jun 2.

    PubMed 37321074

  • McClure T, Lansing A, Ferko N, Wright G, Ghosh SK, Raza S, Kalsekar I, Clarke K, Talenfeld A. A Comparison of Microwave Ablation and Cryoablation for the Treatment of Renal Cell Carcinoma: A Systematic Literature Review and Meta-analysis. Urology. 2023 Oct;180:1-8. doi: 10.1016/j.urology.2023.06.001. Epub 2023 Jun 17.

    PubMed 37331485

  • Cheng PL, Wu PH, Kao WY, Lai YT, Hsu JC, Chiou JF, Wu MH, Lee HL. Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis. Exp Hematol Oncol. 2023 Apr 12;12(1):37. doi: 10.1186/s40164-023-00400-7.

    PubMed 37046292

  • Zhang L, Du F, Zhang Y, Yangdan C, Wang H, Ren L. Microwave ablation is superior to radiofrequency ablation in the treatment of hepatocellular carcinoma below 5 cm - A systematic review and meta-analysis. J Minim Access Surg. 2023 Oct-Dec;19(4):453-458. doi: 10.4103/jmas.jmas_344_22.

    PubMed 37706417

  • Dou Z, Lu F, Ren L, Song X, Li B, Li X. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2022 Jul 29;101(30):e29321. doi: 10.1097/MD.0000000000029321.

    PubMed 35905207

  • Pfannenstiel A, Iannuccilli J, Cornelis FH, Dupuy DE, Beard WL, Prakash P. Shaping the future of microwave tumor ablation: a new direction in precision and control of device performance. Int J Hyperthermia. 2022;39(1):664-674. doi: 10.1080/02656736.2021.1991012.

    PubMed 35465811

  • Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT Jr, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why? Radiographics. 2014 Sep-Oct;34(5):1344-62. doi: 10.1148/rg.345140054.

    PubMed 25208284

  • Granata V, Grassi R, Fusco R, Setola SV, Palaia R, Belli A, Miele V, Brunese L, Grassi R, Petrillo A, Izzo F. Assessment of Ablation Therapy in Pancreatic Cancer: The Radiologist's Challenge. Front Oncol. 2020 Nov 27;10:560952. doi: 10.3389/fonc.2020.560952. eCollection 2020.

    PubMed 33330028

  • Glassberg MB, Ghosh S, Clymer JW, Qadeer RA, Ferko NC, Sadeghirad B, Wright GW, Amaral JF. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther. 2019 Aug 13;12:6407-6438. doi: 10.2147/OTT.S204340. eCollection 2019.

    PubMed 31496742

  • Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005 Oct;25 Suppl 1:S69-83. doi: 10.1148/rg.25si055501.

    PubMed 16227498

  • Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011 Feb;258(2):351-69. doi: 10.1148/radiol.10081634.

    PubMed 21273519

  • Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003 Feb;226(2):441-51. doi: 10.1148/radiol.2262012198.

    PubMed 12563138

  • Dupuy DE, DiPetrillo T, Gandhi S, Ready N, Ng T, Donat W, Mayo-Smith WW. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest. 2006 Mar;129(3):738-45. doi: 10.1378/chest.129.3.738.

    PubMed 16537876

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Ablation and Liver Cancer, run by Varian, a Siemens Healthineers Company.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Trial Manager (5102799833, febasusan.sam@siemens-healthineers.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

30-Day Major Complication Rate (time frame: Treatment to 30 days of follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07900984, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
DUAL Clinical Trial NCT07900984 | AzTrials